New Delhi, Feb 2 (efe-epa).- India, the country with the third highest number of coronavirus deaths at 154,486, recorded 94 fresh ones in the last 24 hours on Tuesday, marking the lowest number since May, according to the health ministry.
The last time India recorded less than 100 coronavirus deaths was on May 15, when the country was still under strict lockdown that lasted until June.
Official numbers show a sharp decline in coronavirus deaths, after recording thousands of them daily in September when the impact of the disease was at its peak in the country.
The number of active cases also shows a downward trend, with 8,635 infections in the last day, a figure moving away from the nearly 100,000 recorded in September, bringing the total to 10.7 million.
In fact, India did not register less than 9,000 cases daily since June 3, when 8,909 active cases were detected.
The fall in the number of Covid-19 deaths and new cases coincide with the rise in the percentage of seroprevalence, mainly in cities that have been hotspots of the infection.
“In the fifth sero survey done in the national capital of Delhi, antibodies have been detected in 56.13 % of population,” the Minister of Health of New Delhi, Satyendar Jain, said on his official Twitter handle.
The national capital, which has been one of the epicenters of the disease in the country, on Tuesday registered only 3 deaths related to the Covid-19, a number much lower than the hundred deaths daily recorded in November.
Although India is the second most affected country by the pandemic, behind the United States, the south Asian nation has one of the highest recovery rates in the world at 97 percent.
This decline in numbers, which poses a relief to the fragile health system of this country of more than 1.3 billion people, comes as the nation begins the third week of its massive vaccination program.
This campaign, which hopes to immunize some 300 million people in the first half of the year, has already inoculated nearly 40 percent of its targeted 10 million health workers in its first phase.
India has been using two vaccines in the campaign, namely Covishield – jointly developed by the British-Swedish pharma company AstraZeneca and the University of Oxford and produced at the Serum Institute of India – and the indigenous Covaxin, developed by Indian lab Bharat Biotech. EFE-EPA